Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H1 2018

  • ID: 4542978
  • Report
  • 925 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • 4SC AG
  • Bio-Path Holdings Inc
  • Erytech Pharma SA
  • Juno Therapeutics Inc
  • Novartis AG
  • Sanofi
  • MORE
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Acute Lymphocytic Leukemia - Pipeline Review, H1 2018, provides an overview of the Acute Lymphocytic Leukemia (Oncology) pipeline landscape.

Acute lymphocytic leukemia (ALL) is the cancer of the white blood cells due to the production of a large number of immature lymphocytes thus blocking the production of normal blood cells. It enters the blood stream and rapidly progress to other parts of the body such as spleen, lymph nodes and liver. Risk factors for ALL include exposure to radiation or chemicals, age, virus infections and genetic factors. Symptoms include anemia, frequent infections, easy bruising, bone pain and breathing problems. Treatment includes chemotherapy, transfusions, transplant and medications.

Report Highlights:

This latest pipeline guide Acute Lymphocytic Leukemia - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Acute Lymphocytic Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Lymphocytic Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 5, 3, 58, 52, 2, 69 and 5 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 1, 15, 19, 13, 3 and 1 molecules, respectively.

Acute Lymphocytic Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Lymphocytic Leukemia (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Acute Lymphocytic Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acute Lymphocytic Leukemia (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acute Lymphocytic Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acute Lymphocytic Leukemia (Oncology)
Reasons to buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acute Lymphocytic Leukemia (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acute Lymphocytic Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 4SC AG
  • Bio-Path Holdings Inc
  • Erytech Pharma SA
  • Juno Therapeutics Inc
  • Novartis AG
  • Sanofi
  • MORE
Introduction

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Overview

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics Development

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics Assessment

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Companies Involved in Therapeutics Development

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Drug Profiles

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Discontinued Products

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by 4SC AG, H1 2018

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by AbbVie Inc, H1 2018

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Actinium Pharmaceuticals Inc, H1 2018

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by ADC Therapeutics SA, H1 2018

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Aeglea BioTherapeutics Inc, H1 2018

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Affimed GmbH, H1 2018

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Altor BioScience Corp, H1 2018

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Amgen Inc, H1 2018

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Angiocrine Bioscience Inc, H1 2018

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by ARA Healthcare Pvt Ltd, H1 2018

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Ariad Pharmaceuticals Inc, H1 2018

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Array BioPharma Inc, H1 2018

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by AstraZeneca Plc, H1 2018

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Atara Biotherapeutics Inc, H1 2018

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Autolus Ltd, H1 2018

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bellicum Pharmaceuticals Inc, H1 2018

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bexion Pharmaceuticals LLC, H1 2018

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bio-Cancer Treatment International Ltd, H1 2018

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bio-Path Holdings Inc, H1 2018

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by BioSight Ltd, H1 2018

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bristol-Myers Squibb Co, H1 2018

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Calithera Biosciences Inc, H1 2018

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by CanBas Co Ltd, H1 2018

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by CARsgen Therapeutics Ltd, H1 2018

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cellectis SA, H1 2018

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cellestia Biotech AG, H1 2018

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cellular Biomedicine Group Inc, H1 2018

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cielo Therapeutics Inc, H1 2018

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cyclacel Pharmaceuticals Inc, H1 2018

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Daiichi Sankyo Co Ltd, H1 2018

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Deciphera Pharmaceuticals LLC, H1 2018

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Eli Lilly and Co, H1 2018

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Enlivex Therapeutics Ltd, H1 2018

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Epizyme Inc, H1 2018

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Erytech Pharma SA, H1 2018

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Fate Therapeutics Inc, H1 2018

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Formula Pharmaceuticals Inc, H1 2018

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Gamida Cell Ltd, H1 2018

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Gilead Sciences Inc, H1 2018

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by GlaxoSmithKline Plc, H1 2018

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by iDD biotech SAS, H1 2018

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by ImmunoGen Inc, H1 2018

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Immunomedics Inc, H1 2018

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Incyte Corp, H1 2018

List of Figures

Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • 4SC AG
  • AbbVie Inc
  • Actinium Pharmaceuticals Inc
  • ADC Therapeutics SA
  • Aeglea BioTherapeutics Inc
  • Affimed GmbH
  • Altor BioScience Corp
  • Amgen Inc
  • Angiocrine Bioscience Inc
  • ARA Healthcare Pvt Ltd
  • Ariad Pharmaceuticals Inc
  • Array BioPharma Inc
  • AstraZeneca Plc
  • Atara Biotherapeutics Inc
  • Autolus Ltd
  • Bellicum Pharmaceuticals Inc
  • Bexion Pharmaceuticals LLC
  • Bio-Cancer Treatment International Ltd
  • Bio-Path Holdings Inc
  • BioSight Ltd
  • Bristol-Myers Squibb Co
  • Calithera Biosciences Inc
  • CanBas Co Ltd
  • CARsgen Therapeutics Ltd
  • Cellectis SA
  • Cellestia Biotech AG
  • Cellular Biomedicine Group Inc
  • Cielo Therapeutics Inc
  • Cyclacel Pharmaceuticals Inc
  • Daiichi Sankyo Co Ltd
  • Deciphera Pharmaceuticals LLC
  • Eli Lilly and Co
  • Enlivex Therapeutics Ltd
  • Epizyme Inc
  • Erytech Pharma SA
  • Fate Therapeutics Inc
  • Formula Pharmaceuticals Inc
  • Gamida Cell Ltd
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • iDD biotech SAS
  • ImmunoGen Inc
  • Immunomedics Inc
  • Incyte Corp
  • Interprotein Corp
  • Jasco Pharmaceuticals LLC
  • Jazz Pharmaceuticals Plc
  • Johnson & Johnson
  • Juno Therapeutics Inc
  • Karyopharm Therapeutics Inc
  • Kiadis Pharma NV
  • Kiromic Inc
  • Kite Pharma Inc
  • Les Laboratoires Servier SAS
  • Lin Bioscience Inc
  • medac GmbH
  • Medivir AB
  • Millennium Pharmaceuticals Inc
  • Miltenyi Biotec GmbH
  • Mitsubishi Tanabe Pharma Corp
  • Molecular Templates Inc
  • NantKwest Inc
  • NBE-Therapeutics AG
  • Nimbus Therapeutics LLC
  • Nohla Therapeutics Inc
  • Novartis AG
  • NovImmune SA
  • Omeros Corp
  • OncoTartis Inc
  • OncoTherapy Science Inc
  • OSE Immunotherapeutics
  • Pascal Biosciences Inc
  • Pfenex Inc
  • Pfizer Inc
  • Pharma Mar SA
  • Polyphor Ltd
  • Protheragen Inc
  • PTC Therapeutics Inc
  • Regeneron Pharmaceuticals Inc
  • Sanofi
  • Sareum Holdings Plc
  • Seattle Genetics Inc
  • SELLAS Life Sciences Group Inc
  • Shire Plc
  • Spectrum Pharmaceuticals Inc
  • Sun Pharma Advanced Research Company Ltd
  • SYNIMMUNE GmbH
  • Syros Pharmaceuticals Inc
  • Takara Bio Inc
  • TCR2 Therapeutics Inc
  • Tolero Pharmaceuticals Inc
  • TRACON Pharmaceuticals Inc
  • Trillium Therapeutics Inc
  • Verastem Inc
  • Xbrane Biopharma AB
  • Xspray Pharma AB
  • ZIOPHARM Oncology Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll